splicing modifier meant to treat SMA because of mutations in chromosome 5q that result in survival motor neuron (SMN) protein deficiency. Evrysdi is administered day by day at home in liquid type by mouth or by feeding tube.Model improvement showed that a pharmacokinetic/pharmacodynamic design having a linear dose outcome was superior to other type